pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca is a pharma organization headquartered in cambridge, GB. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not ap
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
D9102C00001
Phase 2 · small molecule · Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions
D9102C00001 for Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Internal code D9102C00001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AstraZeneca AB
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions
- Status
- active
- Trials
- 1